Skip to main content
Premium Trial:

Request an Annual Quote

Celera, ABI Shares Flogged Following New Strategy Announcement

NEW YORK, April 22 - Shares in Celera Genomics and Applied Biosystems today were lashed after the companies announced a new business strategy that gave ABI marketing and distribution control of Celera's Discovery System.

Also today, Credit Suisse First Boston cut its rating on Celera to a "hold" from a "buy," sending shares tumbling to their lowest level in 2 1/2 years: Celera stock closed down $1.47, or 7.6 percent, to $17.90 on the Nasdaq, surpassing its 52-week low of $18.16. Shares in ABI, meanwhile, fell $2.00, or 8.6 percent, to close at $21.39.

"We believe that this new arrangement transforms Celera from a current revenue generator to a very early stage drug discovery company, and in so doing, reduces the current value of the company," Credit Suisse said in its research note. "We are therefore downgrading the stock from a Buy to a Hold and lowering our price target from $25 to $20."

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.